Boehringer Selects NOVA-EM for Their Global Environmental Monitoring Program
Novatek International has been selected by Boehringer Ingelheim as their approved Vendor and Partner for a worldwide solution for Environmental Monitoring Software. Boehringer Ingelheim plans to implement and validate the NOVA-EM (Environmental Monitoring) solution at multiple sites worldwide.
After considering the time and cost of customizing and configuring their current LIMS and ERP systems to make a customized solution for environmental monitoring (EM), Boehringer Ingelheim decided to go with a dedicated solution for their EM needs.
NOVA-EM from Novatek International was chosen as the global standard by Boehringer Ingelheim following a thorough RFP process, involving several vendors, and evaluation of the available LIMS and EM solutions.
NOVA-EM is Novatek's Solution dedicated to managing all aspects of an automated Environmental Monitoring Program. NOVA-EM is a business ready, process specific "off the shelf" (OTS) solution that meets 95+ percent of environmental monitoring automaton requirements out of the box. As a GAMP 5 category 3 software system, implementing NOVA-EM equates rapid installation, implementation, validation, and deployment. The time and cost savings, in contrast to configurable systems, is undeniable and a key reason for the selection of the NOVA-EM solution.
Novatek's modular approach combined with a globally proven deployment process, provides Boehringer Ingelheim a clear and concise roadmap to plan and add additional off the shelf, process specific modules such as Cleaning Validation Management (NOVA-CVM) to create a larger solution for complete contamination control.
ACD/Labs Collaboration Provides NMR Data to Brazilian Biodiversity Natural Products DatabaseNews
ACD/Labs announces collaboration with researchers at Brazilian Biodiversity database in support of chemical and pharmaceutical R&D.READ MORE
A Promising Framework for Predicting Drug Resistance in CancerNews
The system works by predicting the co-occurrence of about 500 known tumour alterations, as well as their response to over 200 common cancer drugs.READ MORE
IBM Watson Turns Oncogenes Into Drug TargetsNews
Researchers are hoping this icon of artificial intelligence will help people with cancer win as well by providing a rapid, comprehensive report of the genetic mutations at the root of their specific disease and the therapies that target them.READ MORE